Dayton Clinical Oncology Program

Dayton Clinical Oncology Program, Dayton OH

Investigators

Linked publications & trials

Abstract

Dayton Clinical Oncology Program (Dayton NCORP): Project Summary/Abstract The Dayton Clinical Oncology Program, hereafter referred to as “Dayton NCORP”, was incorporated in the State of Ohio in 1983 as a non-profit 501c3 corporation, and one of the original NCI Community Clinical Oncology Programs (CCOP). At that time, a consortium agreement was established between Dayton NCORP, the Dayton area adult hospitals, and Wright State University (WSU). A governing board was established, and corporate bylaws were developed. Kettering Medical Center was the original grantee organization until 2001, when Dayton NCORP subcontracted with WSU for human resources, technical support, and financial oversight. Dayton NCORP contracts with a local accounting firm to conduct an annual external A-133 financial audit. In 2014, Dayton Clinical Oncology Program, was successfully awarded an NCI Community Oncology Research Program (NCORP) Community Site five-year grant. Currently, the Dayton NCORP Board of Directors is led by Principal Investigator Howard M. Gross, M.D. as Chairperson, Roger Wood, M.D., Associate Principal Investigator and Vice Chairperson of the Board, and Mary Ontko, BSN, RN,CCRP, President of the Board and Chief Executive Officer. Other directors represent consortium hospital-members. The Board meets semi-annually to review budget reports and program activities. Our research team is composed of 42 physicians and 3 fellows specializing in medical, surgical, and radiation oncology; 5 nurse practitioners; 13 hospital- and office-based oncology research nurses funded by our member hospitals; and 10 office staff supported by an NCI grant. Over the past 40 years as part of the NCI network, we have built a strong infrastructure supported by long-standing employees who provide comprehensive administrative, regulatory, quality assurance, and research project support to our consortium members. Our research coordinators conduct a secondary eligibility review before any patient enrollment and are responsible for submitting data to the research bases for all enrolled patients. Additionally, we offer pharmacy and specimen support through our on-site pharmacy technician. Dayton NCORP is currently seeking continued funding through the one-year grant extension for August 1, 2025, through July 31, 2026. Continued funding will allow the consortium to continue the Dayton NCORP mission to reduce cancer incidence and mortality through improved treatment and prevention by offering national state-of-the-art cancer research to the local communities. Page 14 Project Summary/Abstract